Nu-Med Plus (NUMD) Restructuring Costs (2023 - 2024)

Nu-Med Plus (NUMD) posted Restructuring Costs of $300.0 for Q1 2024, down 90.0% sequentially from $3000.0 in Q4 2023.

Nu-Med Plus (NUMD) Restructuring Costs (2023 - 2024) Analysis & Trends

Nu-Med Plus has reported Restructuring Costs for 2 years, with the latest figure at $300.0 in Q1 2024.

Quarterly Restructuring Costs changed N/A year-over-year to $300.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $300.0 (changed N/A YoY) and the FY2025 annual result came in at $58.0, down 80.67% from the prior year.
Restructuring Costs declined to $300.0 in Q1 2024 per NUMD's latest filing, from $3000.0 in the prior quarter.
Over five years, Restructuring Costs peaked at $3300.0 in Q3 2023 and troughed at $300.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	199.31 Bn	193.71 Bn	7.27 Bn
2	Stryker	129.55 Bn	126.08 Bn	4.50 Bn
3	Medtronic	119.91 Bn	110.69 Bn	6.41 Bn
4	Boston Scientific	74.06 Bn	73.52 Bn	3.85 Bn
5	Edwards Lifesciences	52.45 Bn	48.20 Bn	1.35 Bn
6	Dexcom	34.60 Bn	32.65 Bn	830.00 Mn
7	GE HealthCare Technologies	33.88 Bn	31.77 Bn	2.18 Bn
8	Koninklijke Philips	26.40 Bn	23.08 Bn	4.55 Bn
9	Steris	23.16 Bn	22.68 Bn	684.20 Mn
10	Nu-Med Plus	1.67 Mn	1.67 Mn	-

Download Data